Biosergen
Biosergen publishes interim report for fourth quarter 2023
REG
Summary of the Interim Report for Q4 2023
| 2023 | 2022 | 2023 | 2022 | |
| TSEK | Oct-Dec | Oct-Dec | Jan-Dec | Jan-Dec |
| Other income | 1.315 | 1.964 | 9.378 | 5.183 |
| Profit/loss before depreciation (EBITDA) | -6.662 | -12.491 | -27.266 | -39.987 |
| Operating profit/loss befor net financials | -6.662 | -12.491 | -27.037 | -39.987 |
| Net financials | 193 | 87 | 229 | 109 |
| Netprofit/loss for the period | -6.469 | -12.432 | -27.037 | -39.906 |
| Earnings per share (SEK) | -0,13 | -0,40 | -0,53 | -1,28 |
Highlights during Q4 2023
- December 12, Biosergen’s Partner Alkem Laboratories Submits Clinical Trial Application for First Patient Study with BSG005 in Invasive Fungal Infections in India as a Rescue Therapy
Highlights after the period
- February 12, Biosergen receives regulatory approval to test lead candidate BSG005 in patients with invasive fungal infection.
- January 30, Biosergen carries out a rights issue of units of approximately SEK 40.5 million, and secures bridge loan
- January 12, Biosergen Announces Leadership Transition: Peder M. Andersen to Step Down as CEO, Tine Olesen Appointed as Successor
The Financial report can be found on our website: https://biosergen.net/investors/filings
| Datum | 2024-02-29, kl 08:35 |
| Källa | Cision |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!